2017-03-009 - 2shRNA - Bifunctional therapeutic shRNAs for drug resistance eradication
Contacts
AO
CH
Acronim & Gínjol codes
2shRNA
2017-03-009
Main technology offer
Designed as a therapeutic strategy to overcome resistance in breast cancer patients treated with anti-HER2+ drugs. TRL4: PoC using cell-line models were successful
Ownership
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
IRB Barcelona adheres to the 3 pillars of ESG, environmental, social and governance, to perform all of their projects with the highest standards
not applicable
Market Data
Problem: Acquired resistance is a major limitation for the successful treatment of breast cancer by targeted therapies. Several drug combinations for the simultaneous attack of primary and secondary pathways have been approved, but they present several problems such as cooperative toxicity effects, lack of efficacy and poor bioavailability, hampers their clinical use and forces the development of new combinatorial approaches. Solution: An alternative approach to traditional combined therapies consists in the simultaneous inactivation of primary and rescue pathways by using short RNA, which trigger the RNA interference machinery (both siRNAs and shRNAs), and avoid the expression of the genes of interest. If technical problems related mostly to biostability and delivery are solved, dual short RNA-based therapies may become the magic bullet to treat cancer.
0
0
0
Licencing and co-development
New technological solutions to overcome cell resistance to treatments.
Funding
In case the project is reactivated, new applied science funds will be needed to generate new IPRights around the technology
Technology Status
Technology RNA-based with potential use as therapy. The 2shRNA nanobinder technology allows to simultaneously knockdown two signalling pathways in cancer cells.
Lack of IPR, need of further maturation in order to be commercially attractive
In case the project is resumed and new IP need to be generated in order to provide a business case.
Patent abandoned
Project currently onhold. Looking for new funding to activate it again.
Additional information
Patents: WO2019086437A1 ; PCT/EP2018/079678 - Date: May 3rd, 2019 Status: Granted URL: https://patents.google.com/patent/WO2019086437A1/en
TRL4 stage: the first proof-of-concept using cell-line models were successful